Korean J Urol.  2010 Feb;51(2):88-93.

Usefulness of the NMP22BladderChek Test for Screening and Follow-up of Bladder Cancer

• Choi HS
• Lee SI
• Kim DJ
• Jeong TY

Abstract

PURPOSE: We evaluated the usefulness of the nuclear matrix protein 22 BladderChek (NMP22BC) test for the screening and follow-up of bladder cancer.
MATERIALS AND METHODS
From February 2006 to September 2009, we enrolled 1,070 patients who had hematuria or who were being followed up for bladder cancer. We compared the sensitivity and specificity of the NMP22BC test with those of urine cytology.
RESULTS
The sensitivity of the NMP22BC test (77.5%) was significantly higher than that of urine cytology (46.3%). The specificity of the NMP22BC test was 88.8%, compared with 97.9% for urine cytology. The sensitivity of the NMP22BC test (81.8%) in non-muscle-invasive bladder cancer was higher than that of cytology (36.4%). However, the sensitivity of the NMP22BC test and of urine cytology in invasive bladder cancer were 57.1% and 92.9%, respectively. The sensitivity of the NMP22BC test was higher for low-grade bladder cancer (83.9%) than for high-grade (62.5%), and the sensitivity of cytology was higher for high-grade bladder cancer (66.7%) than for low-grade (37.5%). Follow-up bladder cancer was detected in 262 patients. The sensitivity of the NMP22BC test in that group (72.7%) was decreased and the specificity (91.7%) was increased. The sensitivity of cytology (54.5%) in the follow-up group was increased and the specificity (95.6%) was decreased. The presence of pyuria was significantly associated with the lower specificity of the NMP22BC test.
CONCLUSIONS
The greater sensitivity of the NMP22BC test may be more useful for the diagnosis of non-muscle-invasive bladder cancer and low-grade bladder cancer than for the diagnosis of invasive or high-grade bladder cancer. If the NMP22BC test is performed in the absence of pyuria, it may play a compensatory role for urine cytology.

Keyword

Nuclear matrix protein 22; Cytology; Urinary bladder neoplasms

MeSH Terms

Follow-Up Studies
Hematuria
Humans
Mass Screening
Nuclear Matrix
Nuclear Proteins
Pyuria
Sensitivity and Specificity
Urinary Bladder
Urinary Bladder Neoplasms
Nuclear Proteins

Reference

1. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983. 130:1083–1086.

2. Park JO, Moon DG, Cheon J, Kim JJ, Yoon DK. Urinary NMP (nuclear matrix protein) 22 in screening and post-treatment follow-up bladder cancer. Korean J Urol. 1999. 40:551–556.

3. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 2005. 66:6 Suppl 1. 35–63.

4. Bassi P, De Marco V, De Lisa A, Mancini M, Pinto F, Bertoloni R, et al. Non-invasive diagnostic tests for bladder cancer: a review of the literature. Urol Int. 2005. 75:193–200.

5. Quek ML, Sanderson K, Daneshmand S, Stein JP. New molecular markers for bladder cnacer detection. Curr Opin Urol. 2004. 14:259–264.

6. Miyanaga N, Akaza H, Ishikawa S, Ohtani M, Noguchi R, Kawai K, et al. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol. 1997. 31:163–168.

7. Murphy WM, Emerson LD, Chandler RW, Moinuddin SM, Soloway MS. Flow cytometry versus urinary cytology in the evaluation of patients with bladder cancer. J Urol. 1986. 136:815–819.

8. Murphy WM, Soloway MS, Jukkola AF, Crabtree WN, Ford KS. Urinary cytology and bladder cancer. The cellular features of transitional cell neoplasms. Cancer. 1984. 53:1555–1565.

9. Kwon DH, Hong SJ. The clinical utility of BTA TRAK, BTA stat, NMP22 and urine cytology in the diagnosis of bladder cancer: a comparative study. Korean J Urol. 2003. 44:721–726.

10. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology. 1998. 52:398–402.

11. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol. 2003. 169:1975–1982.

12. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005. 293:810–816.

13. Tomera KM. NMP22BladderChek test: point-of-care technology with life-and money-saving potential. Expert Rev Mol Diagn. 2004. 4:783–794.

14. Atsü N, Ekici S, Oge O, Ergen A, Hascelik G, Ozen H. False-positive result of the NMP22 test due to hematuria. J Urol. 2002. 167:555–558.

15. Chang SH, Kim YH, Kim ME. Urinary survivin test compared to the nuclear matrix protein (NMP)-22 test and urine cytology for the diagnosis of bladder cancer. Korean J Urol. 2006. 47:1041–1045.

16. Kim H, Chang SG, Kim JI. Significance of urinary NMP22 in patients with bladder tumor as a diagnostic test. Korean J Urol. 1998. 39:450–453.

17. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol. 1999. 162:53–57.

18. Ozer G, Altinel M, Kocak B, Yazicioglu A, Gonenc F. Value of urinary NMP-22 in patients with renal cell carcinoma. Urology. 2002. 60:593–597.